
Tesla Robotaxi Nearing Launch: Buy, Hold or Sell the Stock Now?
Robotaxis — once a sci-fi fantasy — are now becoming a reality. And Tesla TSLA, the world's most valuable EV company, is finally stepping into the arena. The company is preparing to launch its first robotaxi service in Austin, TX, with a tentative start date of June 12.
Using its in-house app, Tesla will allow users to hail a driverless ride, powered entirely by its Full Self-Driving (FSD) software. Tesla CEO Elon Musk recently shared that the company has already begun testing Model Y vehicles — with no one in the driver's seat — on public roads in Austin — and with no reported incidents. He also claimed these vehicles will even deliver themselves to customers starting next month.
While all this sounds exciting, it's worth pausing to take a closer look. Tesla has not shared enough information about how this robotaxi service will actually work. For instance, how many vehicles will be deployed? Will they operate in all weather conditions? And how safe are these driverless Tesla cars really? Given Tesla's history of bold promises and delayed rollouts, investors would be wise to keep expectations in check.
TSLA stock started off 2025 on a rough note, facing a lot of challenges. But over the past month, shares have jumped 23%— likely fueled by optimism surrounding the upcoming robotaxi launch. The hype may already be priced into the stock. Whether Tesla can deliver on the promise remains to be seen.
So, should you buy the stock ahead of this major milestone? Let's take a deeper look.
Can Tesla Catch Up With Waymo's Head Start?
As Tesla's robotaxi service prepares to hit the road, competitors like Alphabet GOOGL already hold an early lead in the driverless race. Alphabet's Waymo currently dominates the U.S. robotaxi market. Waymo is already running commercial services in four U.S. cities—delivering over 250,000 paid rides per week. In fact, Alphabet has committed to investing $5 billion into Waymo over the coming years.
Waymo has also taken a much more cautious and transparent approach compared to Tesla. It has spent months collecting street-level data, testing its vehicles in controlled environments, and publishing detailed safety studies. Tesla, in contrast, has largely relied on the bold statements of CEO Elon Musk, with little public data or independent safety validation to back them up.
Even U.S. regulators are looking for more clarity. The National Highway Traffic Safety Administration (NHTSA) has sent Tesla several questions about the upcoming launch. This comes as Tesla's earlier driver-assist features—Autopilot and FSD—have been linked to hundreds of incidents and over 50 reported deaths.
One area where Tesla could have a competitive edge is cost. Waymo's vehicles are built with high-end sensors like LiDAR and radar, bringing the per-vehicle cost to around $180,000. Tesla's robotaxis, on the other hand, rely solely on cameras and computer vision, cutting estimated production costs to about $50,000. If Tesla's tech proves to be safe and reliable, that pricing advantage could make it easier to scale the service.
Still, despite the buzz, many critical questions remain unanswered as Tesla approaches its robotaxi debut. Besides, the company is already facing growing challenges in its core EV business.
Tesla Sales Slip, Brand Takes a Hit
Tesla is facing declining deliveries across key markets as competition intensifies, from both legacy automakers and aggressive new EV entrants. CEO Elon Musk's political involvement has also drawn criticism, distracting attention from core business operations. Although Musk has since stepped back from his role in the government's Department of Government Efficiency (DOGE), much of the reputational damage may already be done.
As Tesla's sales lose momentum, China's EV giant BYD Co Ltd. BYDDY is gaining ground fast. In the first quarter of 2025, BYD delivered 416,388 battery electric vehicles, beating Tesla's 336,681 units for the second consecutive quarter, cementing its position as the world's top EV maker. With rapid expansion and cutting-edge technology, BYD is posing a serious challenge to Tesla's long-held dominance, while Tesla's brand image appears to be losing some of its shine.
To boost demand, Tesla has been offering deep discounts. However, this strategy is weighing on its automotive profit margins. Musk already walked back the company's 2025 vehicle growth target from 20–30% to more modest expectations on the fourth-quarter earnings call. Now, amid global tariff uncertainty and persistent challenges in China, Tesla hasn't even reaffirmed those lowered targets. The company says it plans to revisit its 2025 delivery guidance in its next quarterly update.
Discouragingly, estimates for Tesla have also been southbound.
Image Source: Zacks Investment Research
TSLA is Quite Pricey Now
From a valuation perspective, Tesla appears overvalued. Going by its price/sales ratio, the company is trading at a forward sales multiple of 10.69, higher than its industry's 2.77.
This premium is difficult to justify based on fundamentals alone. The market is pricing in major breakthroughs in high-risk, unproven areas like autonomous driving and humanoid robotics—bets that are far from guaranteed to pay off.
Tesla is a Risky Investment Now
Tesla's upcoming robotaxi launch may sound like a game-changer, but the details remain murky, and the risks are real. While the company's cost-driven approach could offer scale advantages down the road, it still lags competitors like Waymo in real-world testing, regulatory transparency, and public trust.
Meanwhile, Tesla's core EV business is showing signs of strain, with falling sales, shrinking margins, and intensifying global competition. Add in a premium valuation that hinges on the success of unproven technologies like FSD and robotics, and the case for Tesla looks even weaker.
Despite a recent upside in the stock, much of the robotaxi optimism appears already priced in. Until Tesla shows tangible progress on both the tech and execution fronts, it's too early to invest. For now, this looks more like a time to lock in gains—not double down.
Tesla currently carries a Zacks Rank #5 (Strong Sell).
You can see
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tesla, Inc. (TSLA): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Byd Co., Ltd. (BYDDY): Free Stock Analysis Report

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Article content GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. Article content sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. Article content Article content 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' Article content said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.' Article content The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Article content Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. Article content Article content Article content Email: Article content pr@ Article content For investors and analysts: Article content Article content IR/SR Dept. Article content Article content Article content

CTV News
3 hours ago
- CTV News
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates Prime Minister Carney is calling U.S. President Trump's doubling of steel and aluminum tariffs 'unlawful and unjustified'. Rachel Aiello has the latest.

Globe and Mail
4 hours ago
- Globe and Mail
Oil prices fall as OPEC+ boosts output, tariffs dampen outlook
Oil prices edged lower in early Asian trade on Wednesday, weighed down by a loosening supply-demand balance following increasing OPEC+ output and lingering concerns over the global economic outlook due to tariff tensions. Brent crude futures dipped 5 cents, or 0.1%, to $65.58 a barrel by 0040 GMT while U.S. West Texas Intermediate crude was at $63.32 a barrel, down 9 cents, or 0.1%. Both benchmarks climbed about 2% on Tuesday to a two-week high, supported by worries over supply disruptions from Canadian wildfires and expectations that Iran will reject a U.S. nuclear deal proposal that is key to easing sanctions on the major oil producer. 'Despite fears over Canadian supply and stalled Iran-U.S. nuclear talks, oil markets are struggling to extend gains,' said Tsuyoshi Ueno, senior economist at NLI Research Institute, adding that OPEC+ production increases were capping the upside. Ueno said hopes for progress in U.S.-China trade talks were overshadowed by profit-taking, as investors remained cautious over the broader economic fallout from tariffs. U.S. President Donald Trump and Chinese leader Xi Jinping will likely speak this week, White House press secretary Karoline Leavitt said on Monday, days after Trump accused China of violating an agreement to roll back tariffs and trade restrictions. As the Trump administration pressed U.S. trading partners to provide their best offers by Wednesday, the protracted negotiations and moving deadlines have led economists to scale back growth forecasts. On Tuesday, the Organisation for Economic Co-operation and Development cut its global growth forecast as the fallout from Trump's trade war takes a bigger toll on the U.S. economy. Meanwhile, scores of wildfires have swept across Canada since the start of May, forcing thousands of evacuations and disrupting crude oil production in the country. U.S. crude stocks fell by 3.3 million barrels in the week ended May 30, market sources said, citing American Petroleum Institute figures on Tuesday. Gasoline inventories rose by 4.7 million barrels and distillate stocks rose by about 760,000 barrels. A Reuters poll of nine analysts estimated an average draw of 1 million barrels in crude stocks. Official inventory data from the U.S. Energy Information Administration is due on Wednesday.